Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perifosine in Refractory and Relapsed Leukemia
NCT00391560Phase 2Completed
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Oct 2006
- Primary completion
- Oct 2010
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of perifosine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and 4 more (2 arms), sponsored by COSCIENS Biopharma Inc. Primary endpoint: Overall Response Rate at 4 weeks. Started Oct 2006; status: completed.
02
Drugs
perifosine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)chronic myelomonocytic leukemia (CMML)primary myelofibrosis (PMF)
Beyond the preview
Go deeper on NCT00391560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391560.